A Phase 3 interventional study of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 8 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 24th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2020, is one of 18 in phase 3, and was the 23rd registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
23 studies in Primary Immunodeficiency Diseases by Takeda: 2 open now, 3 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 9 in phase 3, and was the 14th registered.
Takeda’s Primary Immunodeficiency Diseases studies by the year they started, since 2002.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
Among Takeda’s 23 in Primary Immunodeficiency Diseases:
This tab as a report to print or save as PDF → With an account.
In this study, Japanese participants with primary immunodeficiency diseases were treated with Immune Globulin Subcutaneous (Human), 20% solution, (IGSC, 20%). This study will be in 3 parts:
Part 1: Infusions with Immunoglobulin Intravenous (IGIV) every 3 or 4 weeks for 13 weeks.
Part 2: Participants will switch to weekly subcutaneous infusions with IGSC, 20% for 24 weeks.
Part 3: A subset will receive biweekly subcutaneous infusions with IGSC, 20% for 12 weeks.
The main aim of the study is to assess base levels of Immunoglobulin globulin G (IgG) levels in the blood of the participants after weekly and biweekly treatment with IGSC, 20% (in Parts 2 and 3 of the study). Their PID will be treated by their doctor according to their doctor's usual clinical practice.
This study consists of 3 treatment parts (Epoch 1, 2, 3). The total evaluation period of the study will be 57 weeks in which screening period is for 2-8 weeks and Epoch 1 is from Week 8 to Week 21, Epoch 2 is from Week 21 to Week 45, Epoch 3 is from Week 45 to Week 57.
Each participant will receive IGIV treatment in Epoch 1 for a total of 13 weeks, then switch to weekly subcutaneous (SC) treatment with IGSC, 20% in Epoch 2 for a total of 24 weeks and will continue into Epoch 3 for a total of 12 weeks of biweekly SC treatment with IGSC, 20%. Drug dose in Epoch 2 and Epoch 3 will be adjusted so that it will be an equivalent weekly dose of the dose administered in Epoch 1 and twice the dose administrated in Epoch 2 respectively. Epoch 2 will contain two periods, period 1: dose adjustment period (first 12 weeks) and period 2: evaluation period (second 12 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Women of meeting any one of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 to 600 mg/kg of Immunoglobulin Intravenous (IGIV) infusion for every 3 or 4 weeks for up to 13 weeks.
Biological: Immune Globulin Intravenous (IGIV)
Participants who entered to Epoch 2 from Epoch 1 received 50-200 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion once a week up to approximately 24 weeks after Epoch 1.
Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
Participants who entered to Epoch 3 from Epoch 1 received 100-400 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion biweekly up to approximately 12 weeks after Epoch 2.
Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
Participants will receive IGIV infusion.
Also known as: Immune Globulin Infusion (Human)
Drug pages: Immunoglobulins · Solutions
Participants will receive IGSC, 20% SC infusion.
Also known as: Immune Globulin Infusion (Human)
Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2
Total serum trough levels of IgG antibodies measured during period 2 of Epoch 2 were assessed.
Time frame: Epoch 2 (period 2): Up to 24 weeks
Epoch 3: Total Serum Trough Levels of IgG Antibodies
Total serum trough levels of IgG antibodies measured during Epoch 3 were assessed.
Time frame: Epoch 3: Up to Week 12
Epoch 1: Total Serum Trough Levels of IgG Antibodies
Total serum trough levels of IgG antibodies measured during Epoch 1 were assessed.
Time frame: Epoch 1: Up to Week 13
Epoch 2: Area Under the Curve From Time 0 to Last Interval (AUC0-last) for Total Serum Levels of IgG
Time frame: Epoch 2: Week 21
Epoch 2: AUC0-last for Total Serum Levels of IgG Subclasses
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
Time frame: Epoch 2: Week 21
Epoch 2: Apparent Clearance (CL/F) for Total Serum Levels of IgG
Time frame: Epoch 2: Week 21
Epoch 2: CL/F for Total Serum Levels of IgG Subclasses
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
Time frame: Epoch 2: Week 21
Epoch 2: Maximum Concentration (Cmax) for Total Serum Levels of IgG
Time frame: Epoch 2: Week 21
Epoch 2: Cmax for Total Serum Levels of IgG Subclasses
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
Time frame: Epoch 2: Week 21
Epoch 2: Minimum Concentration (Cmin) for Total Serum Levels of IgG
Time frame: Epoch 2: Week 21
Epoch 2: Cmin for Total Serum Levels of IgG Subclasses
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
Time frame: Epoch 2: Week 21
Epoch 2: Time to Maximum Concentration (Tmax) for Total Serum Levels of IgG
Time frame: Epoch 2: Week 21
Epoch 2: Tmax for Total Serum Levels of IgG Subclasses
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
Time frame: Epoch 2: Week 21
Trough Levels of Specific Antibodies to Clinically Relevant Pathogens: Clostridium Tetani Toxoid and Hepatitis B Virus (HBV)
Trough levels of specific antibodies to clinically relevant pathogen (Clostridium tetani toxoid and HBV) were assessed in Epoch 1, Epoch 2 and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.
Time frame: Epoch 1 (Week 1); Epoch 2 (Week 1, 24); Epoch 3 (Week 1, 13)
Trough Levels of Specific Antibodies to Clinically Relevant Pathogen: Haemophilus Influenzae (HIB)
Trough levels of specific antibodies to clinically relevant pathogens (HIB) were assessed in Epoch 1, Epoch 2, and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.
Time frame: Epoch 1 (Week 1); Epoch 2 (Week 1, 24); Epoch 3 (Week 1, 13)
Health Related Quality of Life: Treatment Preference
Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. The questionnaire included following categories: Where do you prefer to receive your immunoglobulin therapy, The frequency of administration, as pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).
Time frame: Up to approximately 1.5 years
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs was defined as adverse events (AEs) with onset after date-time of first dose of study drug, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Any TEAE that is recorded by the investigator as "possibly related" or "probably related" to IP was considered as IGSC, 20%-related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE. AEs included vital signs, clinical laboratory measurements.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Number of Participants With Tolerability Events Related to the Infusion of Study Drug
An infusion is considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to TEAE related to study drug (IGIV or IGSC) infusion. A tolerability event is considered to have occurred if an infusion was not tolerable in Epoch 1, Epoch 2 and Epoch 3. Number of participants with tolerability events related to infusion of IP were assessed.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)
The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Annual Rate of All Infections Per Year
Annual rate is the number of participants reporting any infection per year.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection
Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). The number of days not able to attend school or work to perform normal daily activities due to illness/infection were assessed.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Number of Days Participants Were on Antibiotics
Number of days on antibiotics is defined as the number of days those antibiotics were taken as concomitant medications and is standardized to per year (365.25 days). Antibiotics are defined as any medication under anatomical therapeutic chemical Level 2 therapeutic class "ANTIBACTERIALS FOR SYSTEMIC USE". If a participant took multiple antibiotics on a single day, that day is counted for only once. Protocol defined prophylactic antibiotics for viral, fungal or protozoal infections (e.g. trimethoprim/sulfamethoxazole twice a week for pneumocystis) which are not treated by immunoglobulin, were excluded from this analysis.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Number of Participants Hospitalized Due to Illness or Infection
Number of participants with hospitalization are standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Length of Hospital Stay
Length of hospital stay per stay is standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Number of Acute Physician Visits Due to Illness/Infection
Number of acute physician visits is standardized to per year (365.25 days).
Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)
Health-related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (PedsQL) Total Scale Score
Peds-QL=generic HR QoL instrument designed specifically for pediatrics has domains as:general health/activities,feelings/emotional,social functioning,school functioning.In this study,2-7 years (parent as observer),8-13 years (participant as observer) for Peds-QL health questionnaire was analyzed.Higher scores=better QOL for all domains.This modular instrument used 5-point scale:0(never) to 4(almost always).Items are reversed scored;linearly transformed to 0-100 scale as follows:0=100,1=75,2=50,3=25,4=0.4 dimensions(physical, emotional, social, \& school functioning) are scored.PEDS-QL Total Scale Score has 0-100 scale,higher scores=better HRQoL.
Time frame: Baseline up to end of study (approximately 1.5 years)
EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Total Scale Score
EQ-5D-3L health questionnaire=participant answered questionnaire scoring 5 dimensions -mobility,self-care,usual activities, pain/discomfort and anxiety/depression. n this study, 2-11 years (parent as observer),12 years and older (participant as observer) for EQ-5D-3L health questionnaire was analyzed.Health state index score range from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.EQ visual analogue scale range from 0 to 100, where higher scores indicate better health status.Data is reported as per age groups (2-11 years and \>=12 years).
Time frame: Baseline up to end of the study (approximately 1.5 years)
Health-related Quality of Life (HRQoL): Short Form-36 Health Survey (SF-36) Score
SF-36=generic quality-of-life instrument that has been widely used to assess HRQL of participants.In this study, 14 years and older (participant as observer) for SF-36 health questionnaire was analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases.SF-36=36 items aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100.Higher scores=better HRQL. As pre-specified in protocol data is reported for participants with age group of 14 years or older.
Time frame: Baseline up to end of the study (approximately 1.5 years)
Health Related Quality of Life: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) Score
TSQM=is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain. As pre-specified in protocol, data is reported as per age group (2-12 years and \>=13 years).
Time frame: Baseline up to end of the study (approximately 1.5 years)
Health Related Quality of Life: Treatment Satisfaction Questionnaire for Life Quality Index (LQI) Score
LQI=self-administered questionnaire developed specifically for participants/legal guardians involved in IGIV treatments.2-13 years (parent as observer),14 years and older (participant as observer) for LQI health questionnaire was analyzed.LQI=15-items, divided into 4 domains: treatment interferences(TI)\[6 items\],therapy-related problems(TRP)\[4 items\],therapy setting(TS)\[3 items\];treatment costs(TC)\[2 items\].Items are rated on a 7-point Likert-type scale ranging from 1:"Extremely bad" to 7:"Extremely good".Total scores=0 to 100,higher scores=highest possible satisfaction with factors such as independence,therapy convenience,social/school/work activities;health and travel costs.As pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).All-Treated Set included all enrolled participants of age group '2-13 years' and '\>=14 years' who received at least 1 dose of study drug (IGIV or IGSC).'n'=Number analysed are participants with data available for analysis.
Time frame: Baseline up to end of the study (approximately 1.5 years)
Participants took part in the study at 8 investigative sites in Japan from 11 August 2020 to 22 December 2021.
| Milestone | Epoch 1: IGIV 200-600 mg/kg | Epoch 2: IGSC (20%) 50-200 mg/kg | Epoch 3: IGSC (20%) 100-400 mg/kg |
|---|---|---|---|
| Started | 17 | 0 | 0 |
| Completed | 17 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Epoch 1: IGIV 200-600 mg/kg | Epoch 2: IGSC (20%) 50-200 mg/kg | Epoch 3: IGSC (20%) 100-400 mg/kg |
|---|---|---|---|
| Started | 0 | 17 | 0 |
| Completed | 0 | 15 | 0 |
| Not completed | 0 | 2 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Milestone | Epoch 1: IGIV 200-600 mg/kg | Epoch 2: IGSC (20%) 50-200 mg/kg | Epoch 3: IGSC (20%) 100-400 mg/kg |
|---|---|---|---|
| Started | 0 | 0 | 7 |
| Completed | 0 | 0 | 7 |
| Not completed | 0 | 0 | 0 |
Total serum trough levels of IgG antibodies measured during period 2 of Epoch 2 were assessed.
| grams per liter (g/L) | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2 | 8.56 (8.03 to 9.12) |
Total serum trough levels of IgG antibodies measured during Epoch 3 were assessed.
| g/L | Epoch 3: IGSC (20%) 100-400 mg/kg |
|---|---|
| Epoch 3: Total Serum Trough Levels of IgG Antibodies | 8.39 (7.89 to 8.91) |
Total serum trough levels of IgG antibodies measured during Epoch 1 were assessed.
| g/L | Epoch 1: IGIV 200-600 mg/kg |
|---|---|
| Epoch 1: Total Serum Trough Levels of IgG Antibodies | 8.18 (7.71 to 8.68) |
| g*day/L | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| Epoch 2: Area Under the Curve From Time 0 to Last Interval (AUC0-last) for Total Serum Levels of IgG | 58.9 (48.7 to 71.3) |
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
| g*day/L | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| IgG 1 | 35.8 (32.4 to 39.5) |
| IgG 2 | 23.4 (20.4 to 26.9) |
| IgG 3 | 1.32 (0.624 to 2.80) |
| IgG 4 | 1.67 (1.10 to 2.53) |
| mL/kg/day | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| Epoch 2: Apparent Clearance (CL/F) for Total Serum Levels of IgG | 1.93 (1.71 to 2.19) |
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
| mL/kg/day | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| IgG 1 | 3.18 (2.88 to 3.51) |
| IgG 2 | 4.86 (4.18 to 5.66) |
| IgG 3 | 99.5 (37.1 to 266) |
| IgG 4 | 68.3 (48.3 to 96.6) |
| g/L | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| Epoch 2: Maximum Concentration (Cmax) for Total Serum Levels of IgG | 9.08 (7.46 to 11.1) |
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
| g/L | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| IgG 1 | 5.40 (4.95 to 5.89) |
| IgG 2 | 3.51 (3.06 to 4.03) |
| IgG 3 | 0.202 (0.0960 to 0.425) |
| IgG 4 | 0.256 (0.169 to 0.387) |
| g/L | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| Epoch 2: Minimum Concentration (Cmin) for Total Serum Levels of IgG | 7.45 (6.17 to 8.99) |
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
| g/L | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| IgG 1 | 4.89 (4.34 to 5.51) |
| IgG 2 | 3.15 (2.70 to 3.68) |
| IgG 3 | 0.181 (0.0861 to 0.381) |
| IgG 4 | 0.218 (0.153 to 0.311) |
| hours | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| Epoch 2: Time to Maximum Concentration (Tmax) for Total Serum Levels of IgG | 71.08 (22.82 to 168.23) |
Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.
| hours | Epoch 2: IGSC (20%) 50-200 mg/kg |
|---|---|
| IgG 1 | 71.08 (22.82 to 118.80) |
| IgG 2 | 71.08 (0.00 to 164.32) |
| IgG 3 | 72.92 (71.08 to 118.80) |
| IgG 4 | 71.17 (70.13 to 118.80) |
Trough levels of specific antibodies to clinically relevant pathogen (Clostridium tetani toxoid and HBV) were assessed in Epoch 1, Epoch 2 and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.
| International units (IU)/mL | Epoch 1: IGIV 3-week Interval (Week 1) | Epoch 1: IGIV 4-week Interval (Week 1) | Epoch 2: IGSC, 20% Weekly (Week 1) | Epoch 2: IGSC, 20% Weekly (EOS [Week 24]/ET) | Epoch 3: IGSC, 20% Biweekly (Week 1) | Epoch 3: IGSC, 20% Biweekly (Week 13) |
|---|---|---|---|---|---|---|
| Clostridium Tetani Toxoid | 0.524 (0.290 to 0.949) | 0.602 (0.364 to 0.997) | 0.674 (0.468 to 0.970) | 1.52 (1.11 to 2.08) | 1.97 (1.65 to 2.35) | 1.80 (1.35 to 2.39) |
| Hepatitis B Virus | 27.7 (17.8 to 43.0) | 35.2 (17.5 to 70.9) | 54.1 (33.7 to 87.0) | 486 (335 to 706) | 645 (452 to 920) | 923 (832 to 1020) |
Trough levels of specific antibodies to clinically relevant pathogens (HIB) were assessed in Epoch 1, Epoch 2, and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.
| mg/L | Epoch 1: IGIV 3-week Interval (Week 1) | Epoch 1: IGIV 4-week Interval (Week 1) | Epoch 2: IGSC, 20% Weekly (Week 1) | Epoch 2: IGSC, 20% Weekly (EOS [Week 24]/ET) | Epoch 3: IGSC, 20% Biweekly (Week 1) | Epoch 3: IGSC, 20% Biweekly (Week 13) |
|---|---|---|---|---|---|---|
| Trough Levels of Specific Antibodies to Clinically Relevant Pathogen: Haemophilus Influenzae (HIB) | 1.58 (0.568 to 4.38) | 1.55 (1.11 to 2.18) | 2.50 (1.95 to 3.20) | 1.77 (1.07 to 2.91) | 2.04 (1.74 to 2.39) | 1.73 (1.46 to 2.04) |
Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. The questionnaire included following categories: Where do you prefer to receive your immunoglobulin therapy, The frequency of administration, as pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).
| Participants | IGSC: Epoch 2: 2-13 Years | IGSC: Epoch 2: >=14 Years | IGSC: Epoch 3: 2-13 Years | IGSC: Epoch 3: >=14 Years |
|---|---|---|---|---|
| Where do you Prefer to Receive Your Immunoglobulin Therapy: At Hospital | 0 | 0 | 0 | 1 |
| Where do you Prefer to Receive Your Immunoglobulin Therapy: At Home | 3 | 1 | 1 | 4 |
| Where do you Prefer to Receive Your Immunoglobulin Therapy: No Preference | 1 | 5 | 1 | 0 |
| The Frequency of Administration: Like Very Much | 2 | 1 | 1 | 4 |
| The Frequency of Administration: Like | 1 | 3 | 1 | 1 |
| The Frequency of Administration: No Preference | 1 | 2 | 0 | 0 |
| The Frequency of Administration: Dislike Very Much | 0 | 1 | 0 | 0 |
TEAEs was defined as adverse events (AEs) with onset after date-time of first dose of study drug, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Any TEAE that is recorded by the investigator as "possibly related" or "probably related" to IP was considered as IGSC, 20%-related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE. AEs included vital signs, clinical laboratory measurements.
| Participants | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 11 | 16 | 3 |
An infusion is considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to TEAE related to study drug (IGIV or IGSC) infusion. A tolerability event is considered to have occurred if an infusion was not tolerable in Epoch 1, Epoch 2 and Epoch 3. Number of participants with tolerability events related to infusion of IP were assessed.
| Participants | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Infusions With Infusion Rate Reduced | 0 | 0 | 0 |
| Infusions That Were Interrupted | 0 | 1 | 0 |
| Infusions That Were Stopped | 0 | 0 | 0 |
| Infusions With Infusion Rate Reduced or Interrupted or Stopped | 0 | 1 | 0 |
The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed.
| number of infections per year | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Annual Rate of Validated Acute Serious Bacterial Infections (ASBI) | 0.0 ± 0.00 | 0.25 ± 1.042 | 0.0 ± 0.00 |
Annual rate is the number of participants reporting any infection per year.
| number of infections per year | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Annual Rate of All Infections Per Year | 1.65 ± 2.479 | 2.78 ± 3.074 | 0.00 ± 0.000 |
Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). The number of days not able to attend school or work to perform normal daily activities due to illness/infection were assessed.
| days | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection | 0.00 (0.0 to 16.1) | 0.00 (0.0 to 17.2) | 4.30 (0.0 to 38.7) |
Number of days on antibiotics is defined as the number of days those antibiotics were taken as concomitant medications and is standardized to per year (365.25 days). Antibiotics are defined as any medication under anatomical therapeutic chemical Level 2 therapeutic class "ANTIBACTERIALS FOR SYSTEMIC USE". If a participant took multiple antibiotics on a single day, that day is counted for only once. Protocol defined prophylactic antibiotics for viral, fungal or protozoal infections (e.g. trimethoprim/sulfamethoxazole twice a week for pneumocystis) which are not treated by immunoglobulin, were excluded from this analysis.
| days | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Number of Days Participants Were on Antibiotics | 0.00 (0.0 to 31.8) | 0.00 (0.0 to 34.5) | 0.00 (0.0 to 21.5) |
Number of participants with hospitalization are standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.
| Participants | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Number of Participants Hospitalized Due to Illness or Infection | 0 | 0 | 0 |
Length of hospital stay per stay is standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.
| days | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Length of Hospital Stay | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 17.4) | 0.00 (0.0 to 0.0) |
Number of acute physician visits is standardized to per year (365.25 days).
| number of visits per year | Epoch 1: Immune Globulin Intravenous (IGIV) | Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) | Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) |
|---|---|---|---|
| Number of Acute Physician Visits Due to Illness/Infection | 1.18 ± 3.098 | 3.30 ± 6.807 | 1.624 ± 8.121 |
Peds-QL=generic HR QoL instrument designed specifically for pediatrics has domains as:general health/activities,feelings/emotional,social functioning,school functioning.In this study,2-7 years (parent as observer),8-13 years (participant as observer) for Peds-QL health questionnaire was analyzed.Higher scores=better QOL for all domains.This modular instrument used 5-point scale:0(never) to 4(almost always).Items are reversed scored;linearly transformed to 0-100 scale as follows:0=100,1=75,2=50,3=25,4=0.4 dimensions(physical, emotional, social, \& school functioning) are scored.PEDS-QL Total Scale Score has 0-100 scale,higher scores=better HRQoL.
| score on a scale | Age 2-7 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] | Age 8-13 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] |
|---|---|---|
| IGIV: Epoch 1: Baseline (Week 1) | 88.04 ± 13.835 | 87.23 ± 11.820 |
| IGSC: Epoch 2: Change from Baseline (Week 1) | 9.78 ± 15.372 | -6.79 ± 9.977 |
| IGSC: Epoch 3: Change from Baseline (Week 1) | 14.13 ± NA | 20.65 ± NA |
| IGSC: Epoch 3: Change from Baseline (EOS/ET]) | 3.26 ± 7.686 | 4.08 ± 16.374 |
EQ-5D-3L health questionnaire=participant answered questionnaire scoring 5 dimensions -mobility,self-care,usual activities, pain/discomfort and anxiety/depression. n this study, 2-11 years (parent as observer),12 years and older (participant as observer) for EQ-5D-3L health questionnaire was analyzed.Health state index score range from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.EQ visual analogue scale range from 0 to 100, where higher scores indicate better health status.Data is reported as per age groups (2-11 years and \>=12 years).
| score on a scale | Age 2-11 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] | Age >=12 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] |
|---|---|---|
| IGIV: Epoch 1: Baseline (Week 1): Health State Index Score | 0.8080 ± 0.04619 | 0.8217 ± 0.04544 |
| IGIV: Epoch 1: Baseline (Week 1): EQ Visual Analogue Scale | 87.5 ± 15.55 | 77.1 ± 22.16 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Health State Index Score | -0.0270 ± 0.12275 | 0.0016 ± 0.03318 |
| IGSC: Epoch 2: Change from Baseline (Week 1): EQ Visual Analogue Scale | -5.0 ± 5.00 | 4.2 ± 17.15 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Health State Index Score | 0.0000 ± NA | 0.0133 ± 0.03266 |
| IGSC:Epoch 3: Change from Baseline (Week 1): EQ Visual Analogue Scale | 0.0 ± NA | -1.3 ± 12.39 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Health State Index Score | 0.0400 ± 0.04619 | 0.0229 ± 0.04566 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): EQ Visual Analogue Scale | 1.3 ± 6.29 | 6.9 ± 13.21 |
SF-36=generic quality-of-life instrument that has been widely used to assess HRQL of participants.In this study, 14 years and older (participant as observer) for SF-36 health questionnaire was analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases.SF-36=36 items aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100.Higher scores=better HRQL. As pre-specified in protocol data is reported for participants with age group of 14 years or older.
| score on a scale | Age 14 Years and Above: IGIV 200 to 600 mg/kg + IGSC (20%) 50 to 200 mg/kg and 100 to 400 mg/kg |
|---|---|
| IGIV: Epoch 1: Baseline (Week 1): Physical Component Summary Score | 50.21 ± 7.282 |
| IGIV: Epoch 1: Baseline (Week 1): Mental Component Summary Score | 50.59 ± 8.114 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Physical Component Summary Score | 0.10 ± 7.142 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Mental Component Summary Score | -0.30 ± 2.294 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Physical Component Summary Score | 1.81 ± 8.189 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Mental Component Summary Score | 3.60 ± 5.352 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Physical Component Summary Score | 0.23 ± 4.649 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Mental Component Summary Score | 4.32 ± 8.185 |
TSQM=is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain. As pre-specified in protocol, data is reported as per age group (2-12 years and \>=13 years).
| score on a scale | Age 2-12 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] | Age >=13 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] |
|---|---|---|
| IGIV: Epoch 1: Baseline (Week 1): Effectiveness | 69.44 ± 14.380 | 75.25 ± 18.817 |
| IGIV: Epoch 1: Baseline (Week 1): Convenience | 62.96 ± 13.907 | 65.66 ± 23.016 |
| IGIV: Epoch 1: Baseline (Week 1): Global Satisfaction | 75.00 ± 17.928 | 74.68 ± 18.173 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Effectiveness | 2.22 ± 9.296 | -1.52 ± 10.568 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Convenience | 3.33 ± 16.942 | 5.05 ± 13.484 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Global Satisfaction | -2.86 ± 10.833 | 1.30 ± 10.507 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Effectiveness | 2.78 ± 3.928 | -10.00 ± 52.673 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Convenience | 13.89 ± 19.642 | 15.56 ± 12.669 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Global Satisfaction | -7.14 ± 10.02 | 4.29 ± 29.709 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Effectiveness | 9.26 ± 10.924 | 6.57 ± 18.892 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Convenience | 5.56 ± 22.222 | 9.09 ± 23.210 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Global Satisfaction | 7.14 ± 23.905 | 3.90 ± 23.768 |
LQI=self-administered questionnaire developed specifically for participants/legal guardians involved in IGIV treatments.2-13 years (parent as observer),14 years and older (participant as observer) for LQI health questionnaire was analyzed.LQI=15-items, divided into 4 domains: treatment interferences(TI)\[6 items\],therapy-related problems(TRP)\[4 items\],therapy setting(TS)\[3 items\];treatment costs(TC)\[2 items\].Items are rated on a 7-point Likert-type scale ranging from 1:"Extremely bad" to 7:"Extremely good".Total scores=0 to 100,higher scores=highest possible satisfaction with factors such as independence,therapy convenience,social/school/work activities;health and travel costs.As pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).All-Treated Set included all enrolled participants of age group '2-13 years' and '\>=14 years' who received at least 1 dose of study drug (IGIV or IGSC).'n'=Number analysed are participants with data available for analysis.
| score on a scale | Age 2-13 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] | Age >=14 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg] |
|---|---|---|
| IGIV: Epoch 1: Baseline (Week 1): Factor 1 Treatment Interference | 81.48 ± 14.873 | 77.02 ± 17.963 |
| IGIV: Epoch 1: Baseline (Week 1): Factor 2 Therapy-Related Problems | 81.94 ± 15.516 | 79.17 ± 15.811 |
| IGIV: Epoch 1: Baseline (Week 1): Factor 3 Therapy Setting | 77.78 ± 20.488 | 74.75 ± 23.748 |
| IGIV: Epoch 1: Baseline (Week 1): Factor 4 Treatment Costs | 65.28 ± 24.391 | 53.79 ± 21.847 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Factor 1 Treatment Interference | -8.33 ± 21.445 | -2.53 ± 14.351 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Factor 2 Therapy-Related Problems | 2.78 ± 9.742 | -1.52 ± 15.841 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Factor 3 Therapy Setting | -6.48 ± 30.106 | 0.51 ± 11.773 |
| IGSC: Epoch 2: Change from Baseline (Week 1): Factor 4 Treatment Costs | -9.72 ± 22.618 | 0.76 ± 31.282 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Factor 1 Treatment Interference | 4.17 ± 1.964 | 3.33 ± 4.120 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Factor 2 Therapy-Related Problems | -14.58 ± 14.731 | 1.67 ± 14.613 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Factor 3 Therapy Setting | 19.44 ± 3.928 | 12.22 ± 16.387 |
| IGSC: Epoch 3: Change from Baseline (Week 1): Factor 4 Treatment Costs | 0.00 ± 0.000 | 18.33 ± 40.139 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 1 Treatment Interference | -2.78 ± 13.494 | -0.25 ± 13.046 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 2 Therapy-Related Problems | -1.39 ± 9.001 | 1.14 ± 9.334 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 3 Therapy Setting | 2.78 ± 16.005 | 4.55 ± 16.067 |
| IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 4 Treatment Costs | 4.17 ± 16.672 | 14.39 ± 26.898 |
Collected over From first dose of study drug up to end of study (up to approximately 1.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoch 1: IGIV 200-600 mg/kg | 0/17 (0%) | 0/17 (0%) | 11/17 (64.7%) |
| Epoch 2: IGSC (20%) 50-200 mg/kg | 0/17 (0%) | 0/17 (0%) | 16/17 (94.1%) |
| Epoch 3: IGSC (20%) 100-400 mg/kg | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Event | Epoch 1: IGIV 200-600 mg/kg | Epoch 2: IGSC (20%) 50-200 mg/kg | Epoch 3: IGSC (20%) 100-400 mg/kg |
|---|---|---|---|
| StomatitisGastrointestinal disorders | 3/17 | 1/17 | 0/7 |
| Injection site swellingGeneral disorders | 0/17 | 3/17 | 1/7 |
| Injection site erythemaGeneral disorders | 0/17 | 3/17 | 1/7 |
| HeadacheNervous system disorders | 3/17 | 3/17 | 1/7 |
| Vaccination complicationInjury, poisoning and procedural complications | 0/17 | 1/17 | 1/7 |
| Injection site painGeneral disorders | 0/17 | 2/17 | 0/7 |
| Vaccination site painGeneral disorders | 0/17 | 2/17 | 0/7 |
| NasopharyngitisInfections and infestations | 2/17 | 1/17 | 0/7 |
| ConjunctivitisInfections and infestations | 1/17 | 2/17 | 0/7 |
| GastroenteritisInfections and infestations | 0/17 | 2/17 | 0/7 |
All-Treated Set included all enrolled participants who received at least 1 dose of study drug (IGIV or IGSC).
| Age, Continuous(years) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| Mean | 31.0 ± 21.13 |
| Sex: Female, Male(Participants) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| Female | 7 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 17 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 17 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Weight(kilogram (kg)) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| Mean | 48.16 ± 18.120 |
| Height(centimeter (cm)) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| Mean | 152.15 ± 20.076 |
| Body Mass Index (BMI)(kg/m^2) | IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg |
|---|---|
| Mean | 19.88 ± 3.242 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2020 to primary completion in Dec 2021, 16 months.
Results were first posted in Mar 2024, 2 years 3 months after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulins, Intravenous · Immunoglobulins · Solutions
Primary Immunodeficiency Diseases →